Cold-Start Problems in Data-Driven Prediction of Drug–Drug Interaction Effects

Combining drugs, a phenomenon often referred to as polypharmacy, can induce additional adverse effects. The identification of adverse combinations is a key task in pharmacovigilance. In this context, in silico approaches based on machine learning are promising as they can learn from a limited number...

Full description

Bibliographic Details
Main Authors: Pieter Dewulf, Michiel Stock, Bernard De Baets
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Pharmaceuticals
Subjects:
Online Access:https://www.mdpi.com/1424-8247/14/5/429
id doaj-18eb9c6605c542879e708530f4c1ebda
record_format Article
spelling doaj-18eb9c6605c542879e708530f4c1ebda2021-05-31T23:06:13ZengMDPI AGPharmaceuticals1424-82472021-05-011442942910.3390/ph14050429Cold-Start Problems in Data-Driven Prediction of Drug–Drug Interaction EffectsPieter Dewulf0Michiel Stock1Bernard De Baets2KERMIT, Department of Data Analysis and Mathematical Modelling, Ghent University, Coupure Links 653, 9000 Gent, BelgiumKERMIT, Department of Data Analysis and Mathematical Modelling, Ghent University, Coupure Links 653, 9000 Gent, BelgiumKERMIT, Department of Data Analysis and Mathematical Modelling, Ghent University, Coupure Links 653, 9000 Gent, BelgiumCombining drugs, a phenomenon often referred to as polypharmacy, can induce additional adverse effects. The identification of adverse combinations is a key task in pharmacovigilance. In this context, in silico approaches based on machine learning are promising as they can learn from a limited number of combinations to predict for all. In this work, we identify various subtasks in predicting effects caused by drug–drug interaction. Predicting drug–drug interaction effects for drugs that already exist is very different from predicting outcomes for newly developed drugs, commonly called a cold-start problem. We propose suitable validation schemes for the different subtasks that emerge. These validation schemes are critical to correctly assess the performance. We develop a new model that obtains AUC-ROC <inline-formula><math xmlns="http://www.w3.org/1998/Math/MathML" display="inline"><semantics><mrow><mo>=</mo><mn>0.843</mn></mrow></semantics></math></inline-formula> for the hardest cold-start task up to AUC-ROC <inline-formula><math xmlns="http://www.w3.org/1998/Math/MathML" display="inline"><semantics><mrow><mo>=</mo><mn>0.957</mn></mrow></semantics></math></inline-formula> for the easiest one on the benchmark dataset of Zitnik et al. Finally, we illustrate how our predictions can be used to improve post-market surveillance systems or detect drug–drug interaction effects earlier during drug development.https://www.mdpi.com/1424-8247/14/5/429polypharmacydrug–drug interactionpredictioncross-validationmachine learningcold-start problems
collection DOAJ
language English
format Article
sources DOAJ
author Pieter Dewulf
Michiel Stock
Bernard De Baets
spellingShingle Pieter Dewulf
Michiel Stock
Bernard De Baets
Cold-Start Problems in Data-Driven Prediction of Drug–Drug Interaction Effects
Pharmaceuticals
polypharmacy
drug–drug interaction
prediction
cross-validation
machine learning
cold-start problems
author_facet Pieter Dewulf
Michiel Stock
Bernard De Baets
author_sort Pieter Dewulf
title Cold-Start Problems in Data-Driven Prediction of Drug–Drug Interaction Effects
title_short Cold-Start Problems in Data-Driven Prediction of Drug–Drug Interaction Effects
title_full Cold-Start Problems in Data-Driven Prediction of Drug–Drug Interaction Effects
title_fullStr Cold-Start Problems in Data-Driven Prediction of Drug–Drug Interaction Effects
title_full_unstemmed Cold-Start Problems in Data-Driven Prediction of Drug–Drug Interaction Effects
title_sort cold-start problems in data-driven prediction of drug–drug interaction effects
publisher MDPI AG
series Pharmaceuticals
issn 1424-8247
publishDate 2021-05-01
description Combining drugs, a phenomenon often referred to as polypharmacy, can induce additional adverse effects. The identification of adverse combinations is a key task in pharmacovigilance. In this context, in silico approaches based on machine learning are promising as they can learn from a limited number of combinations to predict for all. In this work, we identify various subtasks in predicting effects caused by drug–drug interaction. Predicting drug–drug interaction effects for drugs that already exist is very different from predicting outcomes for newly developed drugs, commonly called a cold-start problem. We propose suitable validation schemes for the different subtasks that emerge. These validation schemes are critical to correctly assess the performance. We develop a new model that obtains AUC-ROC <inline-formula><math xmlns="http://www.w3.org/1998/Math/MathML" display="inline"><semantics><mrow><mo>=</mo><mn>0.843</mn></mrow></semantics></math></inline-formula> for the hardest cold-start task up to AUC-ROC <inline-formula><math xmlns="http://www.w3.org/1998/Math/MathML" display="inline"><semantics><mrow><mo>=</mo><mn>0.957</mn></mrow></semantics></math></inline-formula> for the easiest one on the benchmark dataset of Zitnik et al. Finally, we illustrate how our predictions can be used to improve post-market surveillance systems or detect drug–drug interaction effects earlier during drug development.
topic polypharmacy
drug–drug interaction
prediction
cross-validation
machine learning
cold-start problems
url https://www.mdpi.com/1424-8247/14/5/429
work_keys_str_mv AT pieterdewulf coldstartproblemsindatadrivenpredictionofdrugdruginteractioneffects
AT michielstock coldstartproblemsindatadrivenpredictionofdrugdruginteractioneffects
AT bernarddebaets coldstartproblemsindatadrivenpredictionofdrugdruginteractioneffects
_version_ 1721418258648662016